Kodiak SciencesKOD
About: Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Employees: 111
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
58% more call options, than puts
Call options by funds: $52K | Put options by funds: $33K
15% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 27
5% less funds holding
Funds holding: 110 [Q1] → 104 (-6) [Q2]
8.95% less ownership
Funds ownership: 85.97% [Q1] → 77.02% (-8.95%) [Q2]
21% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 28
60% less capital invested
Capital invested by funds: $237M [Q1] → $95.1M (-$142M) [Q2]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q1] → 0 (-1) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Matthew Caufield 33% 1-year accuracy 13 / 39 met price target | 22%downside $3 | Neutral Reiterated | 24 Sept 2024 |
HC Wainwright & Co. Matthew Caufield 33% 1-year accuracy 13 / 39 met price target | 22%downside $3 | Neutral Initiated | 5 Sept 2024 |